U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
British Journal of Dermatology2012Vol. 168(1), pp. 192–200
Citations Over TimeTop 10% of 2012 papers
Julia Scarisbrick, Stephen Morris, Richard Azurdia, Tim Illidge, Eileen Parry, R.A.C. GRAHAM-BROWN, Richard Cowan, Eve Gallop‐Evans, Rachel Wachsmuth, Michelle Eagle, Anthony S. Wierzbicki, Handrean Soran, Sean Whittaker, E. Mary Wain
Abstract
Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose.
Related Papers
- → A Naturally Occurring Rexinoid, Honokiol, Can Serve as a Regulator of Various Retinoid X Receptor Heterodimers(2012)35 cited
- → Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor‐Selective Agonists: Novel Halogenated Analogues of 4‐[1‐(3,5,5,8,8‐Pentamethyl‐5,6,7,8‐tetrahydro‐2‐naphthyl)ethynyl]benzoic Acid (Bexarotene)(2012)24 cited
- → Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN(2023)1 cited
- → Assessment of Novel Rexinoids for Therapeutic Potential in Combating Alzheimer's Disease(2020)
- → Development of Novel Bexarotene Analogs for Treating Cutaneous T‐Cell Lymphomas(2021)